Ocugen (NASDAQ: OCGN)
You’re reading a free stock page from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More
Ocugen Returns vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Ocugen Company Info
Ocugen, Inc.
News & Analysis
The company is clearly progressing on several fronts with its pipeline programs.
Ocugen has recently broadened its pipeline.
Select analysts expect these small-caps stocks to catapult higher in the new year.
Could short-sellers be enacting a squeeze?
A prognosticator got less bullish on the company's prospects, and investors took this to heart.
A third-quarter report, complete with clinical updates, is more than enough to satisfy the biotech's bulls.
Can this vaccine maker turn things around?
The company appointed not one, but two new top managers to crucial posts.
Motley Fool Returns
Market-beating stocks from our award-winning analyst team.
Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 04/01/2023.
Discounted offers are only available to new members. Stock Advisor list price is $199 per year.
Calculated by Time-Weighted Return since 2002. Volatility profiles based on trailing-three-year calculations of the standard deviation of service investment returns.
Valuation
Earnings Transcripts
OCGN earnings call for the period ending December 31, 2022.
OCGN earnings call for the period ending September 30, 2022.
OCGN earnings call for the period ending June 30, 2022.
OCGN earnings call for the period ending March 31, 2022.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.